Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted healthc...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Zoltán Kaló, Zoltán Vokó, Andrew Östör, Emma Clifton-Brown, Radu Vasilescu, Alysia Battersby, Edward Gibson
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2017-01-01
Schriftenreihe:	Journal of Market Access & Health Policy
Schlagworte:	Biological disease-modifying antirheumatic drugs (bDMARDs) rheumatoid arthritis reimbursement biosimilars
Online-Zugang:	http://dx.doi.org/10.1080/20016689.2017.1345580
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!